Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,860 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Peer Approaches to Lupus Self-management

NCT03734055
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Quality of Life, Behavior, Health
Interventions
Peer Mentoring, Social Support Group
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery

NCT05853250
View directory record Official record
Conditions
Coronary Artery Diseases, Valvular Heart Diseases
Interventions
Reiki/manual therapy
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BasketballRx: Game Changing Health

NCT07778433
View directory record Official record
Conditions
Pediatric Obesity, Pediatric Overweight, Anxiety, Depression Disorders, Childhood Obesity, Childhood Overweight, Mental Health, Adolescent Obesity
Interventions
BasketballRx
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
10 Years to 15 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 12:29 AM EDT
Suspended Phase 1 Interventional

Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

NCT04309552
View directory record Official record
Conditions
Glioma
Interventions
18F-FMISO PET, 18F-FLT PET
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

NCT04223609
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Placebo, EyeLink 1000 Plus, Oculo-Cognitive Addition test (OCAT), VT3mini - Eye Tracking Technology for OEMs
Drug · Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 59 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CRT-Guanfacine for SPD

NCT02524899
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
Cognitive Remediation Therapy, Guanfacine, Placebo
Behavioral · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Phase 4 Interventional Results available

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

NCT02600715
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions
Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
Drug
Lead sponsor
Edgar LeClaire, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Phase 1 Interventional

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

NCT02639091
View directory record Official record
Conditions
Medical Oncology
Interventions
BAY 94-9343, Pemetrexed, Cisplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Bethesda, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 20, 2026, 12:29 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT06116786
View directory record Official record
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
JNJ-86974680, Cetrelimab, Radiation Therapy
Drug · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Newnan, Georgia • Hackensack, New Jersey • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04075396
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Duarte, California • Orlando, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 12:29 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
IPH4502
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

NCT02083302
View directory record Official record
Conditions
Assaultive Behavior, Violence, Sexual Assault and Rape, Helping Behavior
Interventions
SCREAM Theater Dose 1, SCREAM Theater Doses 2 & SCREAM Theater Dose 3, SCREAM Theater Dose 4
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 21 Years
Enrollment
4,385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 20, 2026, 12:29 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895
View directory record Official record
Conditions
Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
Interventions
Obrixtamig, ZL-1310, Atezolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

NCT01289457
View directory record Official record
Conditions
Leukemia
Interventions
Clofarabine, Idarubicin, Cytarabine, Fludarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 20, 2026, 12:29 AM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

NCT03996473
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Marcos, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 20, 2026, 12:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry

NCT05384470
View directory record Official record
Conditions
Opiate Abuse, Marijuana Abuse, Diagnostic
Interventions
Marihuana, BID2 Instrument - breathalyzer
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Not applicable Interventional Results available

Bilateral Priming for Upper Extremity Hemiparesis in Older Adults

NCT02277028
View directory record Official record
Conditions
Stroke, Upper Extremity Hemiparesis
Interventions
priming and task specific training
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
55 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 20, 2026, 12:29 AM EDT
Suspended Phase 1Phase 2 Interventional

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

NCT03919292
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Neratinib, Divalproex Sodium
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Internal Cues Versus External Cues for Eating and Activity

NCT04025099
View directory record Official record
Conditions
Eating Behavior, Body Image, Diet Habit, Dietary Habits
Interventions
Internal Cues, External Cues
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 20, 2026, 12:29 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor
Interventions
PLN-101095, Pembrolizumab
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
16
States / cities
New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 12:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])

NCT02384200
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infections
Interventions
nitrofurantoin monohydrate/macrocrystalline capsules, ampicillin, gentamicin, vancomycin, ceftriaxone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 20, 2026, 12:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Role of the Locus Coeruleus in Age-related Distractibility

NCT05574634
View directory record Official record
Conditions
Aging, Alzheimer Disease
Interventions
Tablet based adaptive multimodal attention practice program, Tablet based adaptive criterion task practice program
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 20, 2026, 12:29 AM EDT
Recruiting No phase listed Observational

Quality of Pediatric Resuscitation in a Multicenter Collaborative

NCT02708134
View directory record Official record
Conditions
Cardiac Arrest, Cardiopulmonary Arrest
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 18 Years
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
40
States / cities
Los Angeles, California • Madera, California • Orange, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 20, 2026, 12:29 AM EDT